Why Orion Modern Genetics (OMGenetics) Is Superior To 23andMe

2018 Nov, 23 | Source: emyleethai.com

Orion Modern Genetics (OMGenetics) is different than (and superior to) 23andMe in three (3) important ways:

1. OMGenetics testing is always physician ordered and includes complimentary, unlimited genetic counseling. If a client does not have a physician of their own, OMGenetics connects them to an independent 3rd party network of physicians who review the client’s history to determine eligibility for testing. In contrast, 23andMe is a direct-to-consumer (DTC) test which does not require a physician to order and does not include genetic counseling.

2. OMGenetics and 23AndMe use different genomic technologies. 23AndMe uses single nucleotide polymorphisms (SNP) arrays and OMGenetics uses Next Generation Sequencing (NGS). 23andMe uses a SNP genotyping array (from Illumina) that queries ~0.1% of the genome (looking at single nucleotide polymorphisms that have been statistically associated with a number of phenotypes).

OMGenetics uses Illumina’s HiSeq X sequencers in an attempts to return information on over 95% of the 3 billion base pairs of the human genome. 23andMe’s SNP only looks at one or a few base pairs in a gene. But, an average gene has 10,000 base pairs. OMGenetics NGS looks at all 10,000 bases as well as other important variant types. Moreover, if you want to know if you carry a BRCA1 mutation, for example, you need to look at every base pair in the gene. Looking at only few base pairs isn’t very useful since there are 1000s of known pathogenic variants in BRCA1 and novel (never seen before) and private (unique to you) pathogenic variants are very common.

SNP arrays simply were designed to detect these very important types of variants.
• 23andMe’s SNP arrays are like the first generation digital cameras which had a resolution of less than 1MP, which were revolutionary in their time.
• OMGenetics NGS is cutting edge genomic technology and is analogous to the 12MP camera of the iPhone 7.

3. The OMGenetics test is actionable. If you get a positive result there are well-defined, evidence-based clinical guidelines for managing your risk. The OMGenetics test identifies pathogenic variants in genes like BRCA1 or MSH2 which are definitively associated well-defined hereditary cancer syndromes (Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome, respectively), and there are well-established, evidence based guidelines for you and your provider to use to determine the best preventive options for you.

For more information, visit http://www.omgenetics.com

Share on Facebook0Share on Google+0Tweet about this on TwitterShare on LinkedIn0Share on Reddit0Email this to someonePrint this page